Uma Borate | ASCO 2018 | Impact of targeted therapy on treatment of AML


 At the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting, Uma Borate from Knight Cancer Institute Oregon Health & Science University, Portland, US, discusses new targeted therapies for acute myeloid leukemia (AML) including venetoclax in combination with azacitidine, ivosidenib, and enasidenib. 

Download this article:

You can now download this article in Adobe PDF® format.

Download as PDF